[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558844":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":47,"collaborators":19,"id":49,"slug":19,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"University of Erlangen-Nürnberg Medical School","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Treatment","Intervention: Renal denervation",[12],"Device: renal denervation",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DEVICE","renal denervation","ultrasound based renal denervation",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Agnes Bosch, MD","CONTACT","+49 9131 8536207","agnes.bosch@uk-erlangen.de",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Roland E. Schmieder, MD","+499131 8536207","roland.schmieder@uk-erlangen.de",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Friedrich Alexander University Erlangen Nuremberg, Department of Nephrology and Hypertension","RECRUITING","Erlangen","Bavaria","91054","Germany",{"type":39,"coordinates":40},"Point",[41,42],11.00783,49.59099,{"lat":42,"lon":41},[45],{"name":22,"role":23,"phone":46,"phoneExt":19,"email":25},"+49 9131 8536216",{"type":48,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100558844",false,"NCT06556407","Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis","Effect of Renal Denervation on Blood Pressure in Patients With Treatment Resistant Hypertension, End-stage Chronic Kidney Disease and Hemodialysis","RDN-HD","Inclusion Criteria:\n\n* Uncontrolled treatment resistant hypertension (despite intake of 3 different classes of antihypertensive medications) confirmed by 24-h ambulatory blood pressure according to current guidelines (ESH 2023) (office blood pressure ≥ 140\u002F and\u002F or ≥ 90 mmHg and ambulatory blood pressure ≥ 130\u002F and\u002For ≥ 80 mmHg\n* end-stage renal disease on chronic hemodialysis\n* Stable hemodialysis regime for at least 3 months based on the decision of the treating physician\n* Patient is adhering to a stable drug regimen without changes for a minimum of 4 weeks.\n* Individual is ≥ 18 years of age, male and female patients are included.\n\nExclusion Criteria:\n\n* Episodes of sustained systolic and\u002For diastolic hypotension according to 24-h ambulatory blood pressure or dialysis protocols which in the eyes of the treating physician would interfere with a safe renal denervation treatment of the patient\n* Known hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which in the eyes of the interventionalist would interfere with safe catheter placement\n* Prior renal denervation procedure\n* Anatomic or functional solitary kidney, kidney transplantation\n* Severe atherosclerotic disease or artery calcification preventing the assessment of reliable BP measurements\n* Endocrine hypertension other than obstructive sleep apnea\n* Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 3 months of the screening visit\n* Acute episode of systemic and renal disease requiring uptitration of any immunosuppressive drug regimen within the last 3 months\n* Subject is pregnant, nursing, or intends to become pregnant\n* Enrollment in another interventional research protocol.\n* Any condition that, at the discretion of the investigator, would preclude participation in the study (e.g. non-adherence)","ALL","18 Years","99 Years",{"count":60,"type":61},12,"ESTIMATED","INTERVENTIONAL",[64],"NA","The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.",[67,68],"Treatment Resistant Hypertension","Chronic Hemodialysis","2025-09-22",{"date":71,"type":72},"2025-09-26","ACTUAL",{"date":74,"type":72},"2024-03-04",{"date":76,"type":61},"2026-12-01",{"name":5,"class":6},1]